Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation.
Cell Rep
; 37(5): 109942, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1471904
ABSTRACT
Anti-viral monoclonal antibody (mAb) treatments may provide immediate but short-term immunity from coronavirus disease 2019 (COVID-19) in high-risk populations, such as people with diabetes and the elderly; however, data on their efficacy in these populations are limited. We demonstrate that prophylactic mAb treatment blocks viral replication in both the upper and lower respiratory tracts in aged, type 2 diabetic rhesus macaques. mAb infusion dramatically curtails severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-mediated stimulation of interferon-induced chemokines and T cell activation, significantly reducing development of interstitial pneumonia. Furthermore, mAb infusion significantly dampens the greater than 3-fold increase in SARS-CoV-2-induced effector CD4 T cell influx into the cerebrospinal fluid. Our data show that neutralizing mAbs administered preventatively to high-risk populations may mitigate the adverse inflammatory consequences of SARS-CoV-2 exposure.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
SARS-CoV-2
/
COVID-19
/
Anticuerpos Monoclonales
Tipo de estudio:
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Animales
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Cell Rep
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
J.celrep.2021.109942
Similares
MEDLINE
...
LILACS
LIS